Sun, Apr 20, 2014, 3:07 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

factman777 32 posts  |  Last Activity: Mar 20, 2014 5:09 PM Member since: Oct 10, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I left a message yesterday and he called me back this morning.

    He only provides information that is already public which is of course is what he is supposed to do. However, he did say that they have used Root Cause Analysis (RCA) to identify the manufacturing issues with respect to the scaffold and that they are very confident that they will be enrolling subjects in the second quarter of 2014.

    From Wikipedia…

    Root cause analysis (RCA) is a method of problem solving that tries to identify the root causes of faults or problems. RCA practice tries to solve problems by attempting to identify and correct the root causes of events, as opposed to simply addressing their symptoms. Focusing correction on root causes has the goal of preventing problem recurrence.

    Sentiment: Strong Buy

  • Folks, it’s clear and obvious that this human clinical study of its scaffold device is going happen. The rest of the IRB approvals are going to happen and they will get the manufacturing issues with respect to the scaffold corrected.

    Is a time frame of a couple months a long time in the world of biotech investing. I think NOT.

    Great buying opportunity for existing shareholders to add to their positions and for new investors to initiate positions. When they announce their first patient this stock is going over $4 easily.

    Don’t forget that this is an open label clinical trial so results can be reported during the trial of each patient. If even 10% of the nerve tissue can be preserved, it can make a world of difference to the patient’s outcome and quality of life. Even something so small as a patient who is totally paralyzed vs. one who can move a finger to press buttons on a wheel chair is a huge difference … let alone walk across the room as all the African Green monkeys could afterwards.

    Remember, NVIV has tested over 40 paralyzed African Green monkeys and every one of them was able to run again within 3 weeks. These monkeys are excellent models for humans with a genomic similarity in excess of 98%, and the neuro-physiological characteristics of how the spinal cord works in humans as compared to these African Green monkeys is nearly identical.

    Enough said. Time yo buy more share of NVIV.

    Sentiment: Strong Buy

  • Looks like My Astrue took his bonus in InVivo stock instead of cash.

    From the FORM 8-K filed on August 22, 2013.
    "Mr. Astrue will receive a salary at an annual rate of $480,000 and is eligible to receive benefits to the same extent as provided to other senior management employees, including medical and dental benefits. In addition, at the end of the agreement term, subject to his performance of specified objectives, Mr. Astrue will receive a cash bonus equal to 50% of his total salary."

    So 50% of $480,000 is $240,000. On January 10 Mr. Astrue was granted 108,848 shares which is about $2.20 per share (108,848 x 2.20 = $240,000).
    Nice to see Mr. Astrue showing confidence in InVivo going forward.

    Today's closing price of $2.15 is a steal since....

    Clinical trials are set to begin in a couple of months and a significant partnership could be announced for the Hydrogel program in the 2nd quarter. Folks, a couple of months is a very, very short time to wait when you are dealing with biotech stocks.

    Don’t forget that this is an open label clinical trial so results can be reported during the trial of each patient. If even 10% of the nerve tissue can be preserved, it can make a world of difference to the patient’s outcome and quality of life. Even something so small as a patient who is totally paralyzed vs. one who can move a finger to press buttons on a wheel chair is a huge difference … let alone walk across the room as all the African Green monkeys could afterwards.

    Remember, NVIV has tested over 40 paralyzed African Green monkeys and every one of them was able to run again within 3 weeks. These monkeys are excellent models for humans with a genomic similarity in excess of 98%, and the neuro-physiological characteristics of how the spinal cord works in humans as compared to these African Green monkeys is nearly identical.

    Sentiment: Strong Buy

  • Looks like Frank Reynolds is smartening up and realizes that InVivo will be much higher in the near future. His 105b plan to sell 12,000 shares a day expired on Dec 31, 2013 and has not been renewed.

    From the 8K filed in June 2013…
    "On June 11, 2013, Frank M. Reynolds, the Chief Executive Officer of InVivo Therapeutics Holdings Corp. (the "Company"), entered into a pre-arranged trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Rule 10b5-1 Plan"), replacing his existing trading plan, which terminated on June 12, 2013.

    Mr. Reynolds currently owns 13,202,508 shares of Company common stock. During the term of the Rule 10b5-1 Plan, Mr. Reynolds may sell up to 12,000 shares of common stock each trading day. Sales of stock under the Rule 10b5-1 Plan will commence on June 13, 2013 and may continue until the Rule 10b5-1 Plan expires on December 31, 2013. "

    Sentiment: Strong Buy

  • Clinical trials set to begin in a couple of months.

    Don’t forget that this is an open label clinical trial so results can be reported during the trial of each patient. If even 10% of the nerve tissue can be preserved, it can make a world of difference to the patient’s outcome and quality of life. Even something so small as a patient who is totally paralyzed vs. one who can move a finger to press buttons on a wheel chair is a huge difference … let alone walk across the room as all the African Green monkeys could afterwards.

    Remember, NVIV has tested over 40 paralyzed African Green monkeys and every one of them was able to run again within 3 weeks. These monkeys are excellent models for humans with a genomic similarity in excess of 98%, and the neuro-physiological characteristics of how the spinal cord works in humans as compared to these African Green monkeys is nearly identical.

    This management (post-Frank Raynolds) continues to get things done. On Nov 21, 2013 they requested the FDA to expand from three to as many as six sites and the FDA approved the maximum of six as evidenced from the Dec 26, 2013 press release form Invivo:

    "InVivo also plans to send its revised protocol and other supporting materials to six sites next week so that those sites can start their Institutional Review Board reviews and finalize contracts with InVivo."

    Sentiment: Strong Buy

  • NVIV shareholders understand how things are being put in place and that great news is just around the corner.

    Very obvious to me that the Board of Directors knows what it is doing when hiring Interim and Permanent management. And of course, removing the former CEO Frank Reynolds before it became too late to right this ship.

    FDA approval this week and as they say: this rocket ship has just launched. Say good bye to the $2 share.price.

    Sentiment: Strong Buy

  • Looks like most NVIV shareholders understand the word "INTERIM" and know good things are just around the corner.

    Sentiment: Strong Buy

  • factman777 by factman777 Oct 29, 2013 12:19 PM Flag

    No way Mr. Perry leaves ImmunoGen for InVivo unless he sees InVivo as a solid growing company in the future.
    Gerald Perry was hired in January 2009 when Immunogen’s stock price was under $4.50. On the day before his resignation the stock price was $16.48. So Immunogen’s stock price more that tripled during his time there.

    Gregory D. Perry - Base Pay
    $348,708 Bonus + Incentive Comp
    $120,339 Total Cash Compensation
    $469,047
    Stock Award Value
    $0 Option Award Value
    $921,000 Total Equity
    $921,000
    Total Other
    $8,911
    Total for 2012 compensation was 1.3 million.

    Sentiment: Strong Buy

  • factman777 by factman777 Oct 11, 2013 5:28 PM Flag

    There was an order for 155,000 shares at the bid of $1.55 at the close. Hopefully somebody knows something positive a wants to initiate a large position. The order did not execute.

  • Appointing a Non-Executive Chairman is the single most effective step a Board of Directors can take to force sweeping change in governance– a proven drive of higher market value.

    Just Google: "The Value of a Non-Executive Chairman" and check out "The value of a Non-Executive Chairman"

    Sentiment: Strong Buy

  • I love the fact we have some management related to Biogen Idec.

    Biogen Idec helped create an industry that has touched countless lives. We were among the world's first biotechnology companies, and today we are the oldest independent biotech firm in the world. At Biogen Idec, we are proud of our more than 30 years of contributions to the biotechnology industry and look forward to continuing to shape the future of an industry that transforms scientific discovery into advances in patient care.

    Biogen Idec (BIIB) closed at $228.86 today.

    Kenneth DiPietro has been appointed as a member of the Board’s Audit Committee.
    Scroll down to view Kenneth DiPietro…
    Google: "Biogen Idec: About Us: Management"

    John A. McCarthy, Jr. has been appointed as non-executive Chairman of the Board.
    The Value of a Non-Executive Chaiman…
    Google: "The Value of a Non-Executive Chairman"

  • - Bob Langer, the modern day Thomas Edison, is behind InVivo's technology. He would not be involved with any company that would resemble anything close to a scam. Please review his bio...
    Just google: "wiki bob langer"

    - Cash position good until early 2015

    - First patient to be enrolled using its Biopolymer Scaffolding to treat acute SCI is now scheduled for the first quarter of 2014. Since it is an open label study the Company can reports results soon thereafter.

    - Hydrogel technologies have NOT disappeared. Management will provide an update as to the status of those programs as data is available.

    - Uplisting is still on the table. A $2 minimum closing bid price for five consecutive business days is the requirement that needs to be met.

    IMHO, at $2.07 a share I believe InVivo has an excellent risk/reward ratio.

  • What it all boils down to is that we are delayed 3 months with a new CEO that has experience running a biotech company and meeting his stated guidelines. The FDA approved biopolymer scaffolding study is going to happen in the 1st quarter of 2014, the entire Scientific team remains unchanged (including Bob Langer:: google "wikipedia Bob Langer") and we are well funded into 2015.

    April 4, 2013: InVivo Therapeutics Receives Humanitarian Use Device Designation for Spinal Cord Injury Treatment
    April 4, 2013 – Closing Price = 2.75

    April 5, 2013: InVivo Therapeutics Receives Approval from FDA for First Human Trial Using Biomaterials for Traumatic Spinal Cord
    April 5, 2013 – Closing Price = 2.80

    The stock price then DOUBED from here in expectation of the start of the biopolymer scaffolding study. However, this time there will be much more confidence in management starting the study during the first quarter of 2014 and we should have the added kicker of the stock being uplisted along the way.

    And don’t forget, even though the study is over a 15 month period, the results will reported along the way. ANY notable improvement - bladder function, sensation or wiggling of toes, etc. - will be groundbreaking news because the expectation is that all patients who are fully paralyzed before surgery will remain fully paralyzed for life.”

    Any ground breaking news will surely send the stock over $10 and instantly make it a buy-out candidate.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • From rru2a over at InvestrorsHub:

    "Visionaries who are founders of companies are often the perfect "idea man", brilliant and able to create the spark that catalyses the startup of a revolutionary product, but as time goes on many of them do not fit the mold of a product manager, since their creativity and enthusiasm can get in the way of the boring details of just running the company with a dry focus on execution, coordination of plans and projections, and handling of commercial business deals including product launch. At later stages of company growth, the ideal "idea man" is better off passing the torch to an experienced industry CEO when the time comes.

    The lifecycle of a revolutionary developmental stage biotech is very susceptible to this phenomenon. A brilliant researcher can be the brains or inspiration behind the company, but sooner or later the company needs someone with expert experience with the real world to coordinate and execute on product launches."

    As evidenced by the market reaction this morning, this may be one of the last few times to buy under $4.00 before the several "catalysts" are executed in the months ahead.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Just to refresh our memories so we don't panic sell, Bob Langer, the modern day Thomas Edison, is the man behind the science at InVivo.

    Here is a little background on Mr. Langer who is on InVivo's Scientific Advisory Board:

    Robert S. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT) (being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer has written over 1,100 articles. He also has approximately 760 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology and medical device companies.

    He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 — 2002 and as its Chairman from 1999- 2002.

    Dr. Langer has received over 180 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers and the 2008 Millennium Prize, the world’s most prestigious technology prize. He is the also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize.

    Forbes Magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Dr. Langer as one of the 15 innovators worldwide who will reinvent our future. Time Magazine and CNN (2001) named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best). Parade Magazine (2004) selected Dr. Langer as one of 6 “Heroes whose research may save your life.”

    Just the facts,
    -FactMan777

  • Frank Reynolds has been in a lot of pain. From the 2010 article: “What Makes Frank Run”…

    “The scar on Reynolds' back starts between his buttocks and runs in a ragged line 14 inches to the middle of his back. It's a constant reminder of what he is trying to accomplish. So is the pain. The stainless-steel screws that hold his spine together sit just beneath his skin; when they get cold, he says, "it feels like a little bomb in there." In the area in which surgeons cut away bone to relieve pressure on his swelling spinal cord, he says, "The only thing between me and my spinal cord is muscle, fat, and skin. If you had a stick, you could actually paralyze me." It could be a distraction -- the hole in your back, the pain, the awareness that your own damaged spinal tissue is gradually degenerating. It's what keeps Reynolds focused.”

    Great time to initiate/add to a position if the stock falls below $3.80. Remember Bob Langer, the modern day Thomas Edison, is behind the science at InVivo. And they will eventually get uplisted.

    Just the Facts,
    -FactMan777

    Sentiment: Strong Buy

  • factman777 factman777 Jun 14, 2013 2:08 PM Flag

    Those who bought those 12K shares everyday and double their money in a few months should sent a thank you email to Frank for selling he shares at wholesale prices. Because once this get uplisted, the trials start and the News media get involved, this stock should be an easy double from here.

    Sentiment: Strong Buy

  • Dr. Robert S. Langer is the man behind InVivo's Scaffold Technology.

    He follows Morgan Freeman at about 01:20:00

    bu.edu/commencement/2013/05/19/2013-commencement-archive/

    Just the facts,
    -FactMan777

  • Traffic Control.
    Each stock market has its own traffic control police officer. Yup, that's right, just as a broken traffic light needs a person to control the flow of cars, each exchange requires people who are at the "intersection" where buyers and sellers "meet," or place their orders. The traffic controllers of both exchanges deal with specific traffic problems and, in turn, make it possible for their markets to work. On the Nasdaq, the traffic controller is known as the market maker, who, we already mentioned, transacts with buyers and sellers to keep the flow of trading going. On the NYSE, the exchange traffic controller is known as the specialist, who is in charge of matching up buyers and sellers.

    The definitions of the role of the market maker and that of the specialist are technically different; a market maker creates a market for a security, whereas a specialist merely facilitates it. However, the duty of both the market maker and specialist is to ensure smooth and orderly markets for clients. If too many orders get backed up, the traffic controllers of the exchanges will work to match the bidders with the askers to ensure the completion of as many orders as possible. If there is nobody willing to buy or sell, the market makers of the Nasdaq and the specialists of the NYSE will try to see if they can find buyers and sellers and even buy and sell from their own inventories.

    Perception and Cost
    The Nasdaq is typically known as a high-tech market, attracting many of the firms dealing with the internet or electronics. Accordingly, the stocks on this exchange are considered to be more volatile and growth oriented. On the other hand, the companies on NYSE are perceived to be more well established. Its listings include many of the blue chip firms and industrials that were around before our parents, and its stocks are considered to be more stable and established.

    -FactMan777

    Sentiment: Strong Buy

  • Location, Location, Location
    The location of an exchange refers not so much to its street address but the "place" where its transactions take place. On the NYSE, all trades occur in a physical place, on the trading floor in New York City. So, when you see those guys waving their hands on TV or ringing a bell before opening the exchange, you are seeing the people through whom stocks are transacted on the NYSE.

    The Nasdaq, on the other hand, is located not on a physical trading floor but on a telecommunications network. People are not on a floor of the exchange matching buy and sell orders on behalf of investors. Instead, trading takes place directly between investors and their buyers or sellers, who are the market makers (whose role we discuss below in the next section), through an elaborate system of companies electronically connected to one another.

    Dealer Vs. Auction Market
    The fundamental difference between the NYSE and Nasdaq is in the way securities on the exchanges are transacted between buyers and sellers. The Nasdaq is a dealer's market, wherein market participants are not buying from and selling to one another directly but through a dealer, who, in the case of the Nasdaq, is a market maker. The NYSE is an auction market, wherein individuals are typically buying and selling between one another and there is an auction occurring; that is, the highest bidding price will be matched with the lowest asking price.

    Continued..

    -FactMan777.

    Sentiment: Strong Buy

NVIV
1.60+0.02(+1.27%)Apr 17 3:43 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AsiaInfo-Linkage, Inc.
NasdaqGSWed, Jan 15, 2014 4:00 PM EST
The ExOne Company
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT